NewsBenzingaImmunityBio And Rafa Laboratories Say Israeli MoH Grants Approval For ANKTIVA, Indicated In Combination With BCG For Treatment Of Adult Patients With BCG-Unresponsive NMIBC With CIS With Or Without Papillary Tumors ImmunityBio And Rafa Laboratories Say Israeli MoH Grants Approval For ANKTIVA, Indicated In Combination With BCG For Treatment Of Adult Patients With BCG-Unresponsive NMIBC With CIS With Or Without Papillary Tumors Benzinga 2026.11.09 12:23 (GMT+0) Open on Benzinga Other news Barclays Downgrades Fresenius Medical Care to Underweight Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields Monte Rosa Therapeutics Presents Preclinical Data Of MRT-8102 At ACR Convergence 2026 B of A Securities Initiates Coverage On Supernus with Buy Rating, Announces Price Target of $47 Freedom Broker Upgrades Dnow to Buy, Maintains Price Target to $18 Trade Desk Likely To Report Lower Q3 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
Trade Desk Likely To Report Lower Q3 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
